Literature DB >> 7923555

Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

G Scambia1, F O Ranelletti, P B Panici, R De Vincenzo, G Bonanno, G Ferrandina, M Piantelli, S Bussa, C Rumi, M Cianfriglia.   

Abstract

This study demonstrates that the flavonoid quercetin (Q), a plant-derived compound with low toxicity in vivo, greatly potentiates the growth-inhibitory activity of Adriamycin (ADR) on MCF-7 ADR-resistant human breast cancer cells. The effect of Q was dose-dependent at concentrations ranging between 1 and 10 microM. Since ADR resistance in these cells is associated with the expression of high levels of P-glycoprotein (Pgp), we evaluated the effect of Q and related flavonoids of Pgp activity in cytofluorographic efflux experiments with the fluorescent dye rhodamine 123 (Rh 123). Our results indicate that Q and 3-OMe Q (3',4',7-trimethoxyquercetin) but not the 3-rhamnosylglucoside of Q (rutin) inhibit the Pgp pump-efflux activity in a dose-related manner. Moreover, 10 microM Q reduces the expression of the immunoreactive Pgp in MCF-7 ADR-resistant cells as evaluated by cytofluorimetric assay. In conclusion, these findings provide a further biological basis for the potential therapeutic application of Q as an anti-cancer drug either alone or in combination with ADR in multidrug-resistant breast tumor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923555     DOI: 10.1007/bf00685655

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  38 in total

1.  Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.

Authors:  R L Miller; R M Bukowski; G T Budd; J Purvis; J K Weick; K Shepard; K K Midha; R Ganapathi
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

2.  Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II).

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; N Maggiano; A Capelli; S Mancuso
Journal:  Gynecol Oncol       Date:  1992-04       Impact factor: 5.482

3.  Adverse interactions between cytotoxic drugs and hormonal agents in human breast cancer cells.

Authors:  R Clarke; H W van der Berg
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

Authors:  T P Miller; T M Grogan; W S Dalton; C M Spier; R J Scheper; S E Salmon
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

5.  The roles of DNA polymerases alpha, beta, and gamma in DNA repair synthesis induced in hamster and human cells by different DNA damaging agents.

Authors:  M R Miller; D N Chinault
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

6.  Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin.

Authors:  J Hofmann; H H Fiebig; B R Winterhalter; D P Berger; H Grunicke
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

7.  Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123.

Authors:  C Ludescher; J Thaler; D Drach; J Drach; M Spitaler; C Gattringer; H Huber; J Hofmann
Journal:  Br J Haematol       Date:  1992-09       Impact factor: 6.998

8.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

9.  A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.

Authors:  P J Vickers; R B Dickson; R Shoemaker; K H Cowan
Journal:  Mol Endocrinol       Date:  1988-10

10.  Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.

Authors:  G Scambia; F O Ranelletti; P B Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; C Rumi; L M Larocca; S Mancuso
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

View more
  45 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin.

Authors:  J M Pérez-Victoria; F J Pérez-Victoria; G Conseil; M Maitrejean; G Comte; D Barron; A Di Pietro; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 4.  Bioavailability enhancers of herbal origin: an overview.

Authors:  Kritika Kesarwani; Rajiv Gupta; Alok Mukerjee
Journal:  Asian Pac J Trop Biomed       Date:  2013-04

5.  Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.

Authors:  V A Eagling; L Profit; D J Back
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 7.  Using purified P-glycoprotein to understand multidrug resistance.

Authors:  A B Shapiro; V Ling
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

8.  Quercetin not only inhibits P-glycoprotein efflux activity but also inhibits CYP3A isozymes.

Authors:  M A Sarkar
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein.

Authors:  G Conseil; H Baubichon-Cortay; G Dayan; J M Jault; D Barron; A Di Pietro
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Reversal of efflux of an anticancer drug in human drug-resistant breast cancer cells by inhibition of protein kinase Cα (PKCα) activity.

Authors:  Chan Woo Kim; Daisuke Asai; Jeong-Hun Kang; Akihiro Kishimura; Takeshi Mori; Yoshiki Katayama
Journal:  Tumour Biol       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.